PLX's Uplyso actually did switchover study with Cerezyme, nothing unusual occured. And Uplyso was manufactured entirely differently from Cerezyme.
There are big financial stakes on the line for many companies. There will always be for and against anything proposed. I wouldn't say switchover back and forth is big concern. I do agree for really complex biologic, the switchover should be strictly under physician's supervision, at least initially. This shouldn't be a problem because really complex biologics are administered at doctor's office or hospital anyway.
Market Data 
Markets 
AI
